中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (8): 583-586.doi: 10.12144/zgmfskin202508583

• 临床研究 • 上一篇    下一篇

生物制剂或小分子靶向药物治疗难治性毛发红糠疹六例疗效评价

周萌,索盼盼,刘保国,吕超,王鑫,苗国英   

  1. 河北工程大学附属医院皮肤中心，河北省免疫性皮肤病重点实验室(SZX2019002)，河北邯郸，056002
  • 出版日期:2025-08-15 发布日期:2025-07-31

Efficacy of biological agents or small molecular targeted drugs in the treatment of 6 cases with refractory pityriasis rubra pilaris

ZHOU Meng, SUO Panpan, LIU Baoguo, LYU Chao, WANG Xin, MIAO Guoying   

  1. Department of Dermatology, Affiliated Hospital of Hebei Engineering University, Key Laboratory of Immune Skin Diseases of Hebei Province (SZX2019002), Handan 056002, China
  • Online:2025-08-15 Published:2025-07-31

PDF (PC)

23

摘要： 目的：评价生物制剂或小分子靶向药物治疗难治性毛发红糠疹（PRP）的疗效及安全性。方法：回顾性分析2020年1月至2023年12月就诊于我院的PRP患者的临床资料，所有患者均接受过系统治疗但效果欠佳。本文中治疗药物包括司库奇尤单抗、托法替布或阿普米司特。通过银屑病皮损面积和严重度指数（PASI）评分评估疗效，记录治疗起效时间、达标率、最终改善率及不良反应。结果：共分析6例患者，其中1例给予司库奇尤单抗，1例给予阿普米司特，2例给予托法替布，2例给予阿普米司特联合阿维A治疗。治疗4周时，4例达到PASI 50。随访32~54周，最终PASI改善率达PASI 90 2例、PASI 75 4例。所有患者均未出现严重不良反应。结论：生物制剂及小分子靶向药物治疗难治性PRP疗效显著，且安全性好。

关键词: 毛发红糠疹, 司库奇尤单抗, 托法替布, 阿普米司特

Abstract: Objective: To evaluate the efficacy and safety of biological agents or small molecular targeted drugs in the treatment of refractory pityriasis rubra pilaris(PRP). Methods: A retrospective analysis was conducted on the clinical data of PRP patients who visited our hospital from January 2020 to December 2023. All patients had received systematic treatment but the effect was not satisfactory. Therapeutic drugs in this study included secukinumab, tofacitinib citrate or apremilast treatment. The therapeutic effect was evaluated by the psoriasis Lesion Area and Severity Index (PASI) score. The onset time of treatment, the rate of reaching the target, the final improvement rate and adverse reactions were recorded. Results: A total of six patients were analyzed, among whom one was treated with secukinumab, two with tofacitinib citrate, one with apremilast, and two with apremilast combined with acitretin. At 4 weeks of treatment, 4 cases achieved PASI50. During the follow-up period of 32-54 weeks, 2 patients achieved PASI 90, 4 reached PASI 75. No serious adverse reactions occurred in all patients. Conclusions: Biological agents and small molecule targeted drugs have significant efficacy and good safety in the treatment of refractory PRP.

Key words: pityriasis rubra pilaris, secukinumab, tofacitinib, apremilast